The effects of calcitonin in hypercalcemia in patients with malignancy

Porcine calcitonin (PC) is a potent serum calcium lowering agent in human subjects with hypercalcemia. Hypercalcemia in patients with neoplasia was temporarily corrected with these agents until more definitive measures were instituted to control their neoplastic disease. Of the 10 hypercalcemic pati...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1974-10, Vol.34 (4), p.1268-1271
Main Authors: Vaughn, Clarence B., Vaitkevicius, Vainutis K.
Format: Article
Language:English
Subjects:
Animals
Bone Neoplasms - complications
Calcitonin - administration & dosage
Calcitonin - therapeutic use
Calcium - blood
Calcium - urine
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Injections, Intramuscular
Injections, Intravenous
Neoplasm Metastasis
Neoplasms - complications
Phosphorus - blood
Phosphorus - urine
Swine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Porcine calcitonin (PC) is a potent serum calcium lowering agent in human subjects with hypercalcemia. Hypercalcemia in patients with neoplasia was temporarily corrected with these agents until more definitive measures were instituted to control their neoplastic disease. Of the 10 hypercalcemic patients administered calcitonin I.M. every 4–6 hours or as a 24‐hour I.V. infusion, 9 who were treated with PC experienced depressed serum calcium levels. The average change in serum calcium was –2.9 mg/100 ml. The dose range of calcitonin, 2–8 Medical Research Council Units (MRUC)/kg disclosed no adverse systemic or hypersensitive reactions to the drug. This study further confirmed that calcitonin affects both kidney and bone. These findings suggest that calcitonin has great potential as an effective therapeutic agent in the treatment of hypercalcemia.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(197410)34:4<1268::AID-CNCR2820340437>3.0.CO;2-X